Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.3.0.814
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Aug. 31, 2015
Aug. 31, 2014
Statement of Cash Flows [Abstract]    
Net income $ 8,325,774 $ 849,457
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization expense 174,964 287,010
Abandonment of patents   25,649
Compensatory element of stock options 304,585 255,380
Provision for doubtful accounts 149,596 913,235
Equity in losses of affiliate 17,660 242,318
Deferred income tax benefit (6,956,834)  
Changes in assets and liabilities:    
Accounts receivable (240,369) (1,527,397)
Notes receivable   550,782
Prepaid expenses 159,163 59,927
Inventory 53,746 15,973
Other current assets 25,483 29,145
Deposits and other assets, net 10,548 52,628
Accounts payable 455,532 (156,306)
Accrued expenses (789,783) (657,576)
Deferred revenue 1,173,443 371,511
Net cash provided by operating activities 2,863,508 1,311,736
Cash flows from investing activities:    
Release of restricted cash held in escrow (148) 764,045
Purchases of property and equipment (54,691) (93,478)
Purchase of Prepacyte®-CB (212,203)  
Purchases of marketable securities and other investments, net (214,520) (84,753)
Investment in affiliate   (150,000)
Net cash (used in) provided by investing activities (481,562) 435,814
Cash flows from financing activities:    
Treasury stock purchases (2,946,705) (2,294,631)
Repayments of note payable (49,145)  
Proceeds from the exercise of stock options 54,100 70,902
Net cash used in financing activities (2,941,750) (2,223,729)
Increase (decrease) in cash and cash equivalents (559,804) (476,179)
Cash and cash equivalents - beginning of period 3,279,267 3,925,156
Cash and cash equivalents - end of period 2,719,463 3,448,977
Supplemental non-cash investing activities:    
Unrealized gain on marketable securities 143,318 0
Disposition of Cryo-Cell common stock held by Saneron, increase in investment   $ 74,764
Increase in note payable in connection with the purchased business 1,300,000  
Increase in accrued expenses in connection with the purchased business 586,675  
Decrease in prepaid expenses in connection with the purchased business $ 104,000